Memantine (Namenda): Uses, Dosing, Side Effects, and How It Compares to Other Cognitive Medications

What Is Memantine and How Does It Work?

Memantine is a low-to-moderate affinity, uncompetitive antagonist at N-methyl-D-aspartate (NMDA) glutamate receptors. It enters open ion channels, blocks pathological calcium influx, and leaves quickly enough during normal synaptic firing not to interfere with learning signals. This kinetic profile separates it from earlier NMDA blockers like ketamine and phencyclidine, which bind tightly and produce profound psychotomimetic effects.

In Alzheimer's disease, chronically elevated ambient glutamate produces sustained low-level NMDA activation. That "background noise" desensitizes receptors, obscures meaningful signal-to-noise differences between active and resting synapses, and accelerates excitotoxic neuronal loss. Memantine damps that tonic noise without silencing the phasic bursts that encode new memories.

The FDA granted approval based on a key 28-week trial (Reisberg et al., 2003, N=252) in which memantine-treated patients showed a statistically significant advantage on the Severe Impairment Battery (SIB) and the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) compared with placebo [1]. Effect sizes were modest: mean SIB improvement of 5.7 points versus a 6.0-point decline in placebo (P<0.001). Modest does not mean meaningless in a disease that otherwise progresses relentlessly.

Memantine has no cholinesterase-inhibitor activity and does not raise acetylcholine levels. Physicians who want both mechanisms often prescribe the combination capsule Namzaric, which pairs memantine XR 28 mg with donepezil 10 mg.

FDA-Approved Indications and Off-Label Prescribing

The only FDA-approved indication for memantine is moderate-to-severe Alzheimer's disease in adults [2]. "Moderate to severe" is operationally defined as a Mini-Mental State Examination (MMSE) score of 3 to 14, though clinical judgment governs individual cases.

Off-label uses studied in peer-reviewed literature include:

• Vascular dementia. A 2006 Cochrane review found small, statistically significant but clinically uncertain benefits on cognition and global outcomes [3].
• Mild cognitive impairment (MCI). The MCI-SIM trial and several other randomized studies found no significant benefit over placebo in patients with MMSE scores above 20. Current practice guidelines from the American Academy of Neurology do not recommend memantine for MCI.
• Obsessive-compulsive disorder (OCD) augmentation. Small open-label trials suggest benefit as add-on to serotonin reuptake inhibitors, but no large RCT has confirmed this.
• Autism spectrum disorder. Results from the MemAD trial and independent pilots are mixed. The FDA has not approved this use.
• ADHD. Case series and one small RCT (Findling et al., 2007, N=40) showed modest improvement in inattention ratings, but effect sizes were well below those seen with stimulants.

Prescribers should document the rationale and obtain informed consent before initiating any off-label use.

Dosing and Titration for Memantine

The standard titration schedule for the immediate-release formulation begins at 5 mg once daily for one week, increases to 5 mg twice daily in week two, to 5 mg and 10 mg (morning and evening) in week three, and reaches the target of 10 mg twice daily (20 mg/day total) in week four [2]. The extended-release capsule (Namenda XR) starts at 7 mg once daily and increases by 7 mg weekly to the 28 mg/day target, which approximates the same total daily exposure.

Renal impairment significantly affects clearance. For patients with a creatinine clearance (CrCl) <30 mL/min, the FDA label specifies a maximum dose of 5 mg twice daily for IR, or 14 mg/day for XR [2]. No dose adjustment is needed for mild-to-moderate hepatic impairment, but memantine is not well studied in severe liver disease.

Alkaline urine slows renal elimination and may raise plasma levels; conditions or diets that substantially increase urinary pH (e.g., carbonic anhydrase inhibitors, sodium bicarbonate supplementation) warrant monitoring.

Clinical Efficacy: What the Trials Actually Show

The key Reisberg trial remains the cornerstone evidence for approval. In 252 patients with moderate-to-severe Alzheimer's disease randomized to memantine 20 mg/day or placebo over 28 weeks, the memantine group scored 5.7 points higher on the SIB and showed significantly better CIBIC-Plus ratings (P<0.001) [1].

A Cochrane meta-analysis published in 2019 (McShane et al., pooling 10 trials, N=2,959) concluded: "Memantine has a small beneficial effect on cognition, behavior, and the ability to perform activities of daily living at 6 months in people with moderate to severe Alzheimer's disease" [3]. The effect on cognition corresponds roughly to an ADAS-Cog difference of 1.4 points, which sits below many clinicians' threshold for clinical significance but above placebo noise.

The MEM-MD-02 trial (N=433 to 24 weeks) tested memantine in mild-to-moderate Alzheimer's disease and found no statistically significant advantage over placebo on the primary ADAS-Cog outcome, reinforcing the current label restriction to moderate-to-severe disease [4].

Combination therapy data from the DOMINO-AD trial (Howard et al., NEJM, 2012, N=295) compared continued donepezil, added memantine, both, or neither in patients who had reached moderate-to-severe disease after at least three years on donepezil. Continuing donepezil, adding memantine, or both produced significantly better outcomes on the SMMSE and Bristol Activities of Daily Living Scale than discontinuation alone. The combination showed additive but not synergistic benefit [5].

"The data support the use of memantine in moderate-to-severe Alzheimer's disease and are consistent with combined cholinesterase inhibitor and memantine treatment," wrote Howard and colleagues in their NEJM report [5].

Side Effects and Safety Profile

Memantine is generally well tolerated. In pooled trials, the most common adverse events occurring more frequently with memantine than placebo were dizziness (7% vs. 5%), headache (6% vs. 3%), confusion (6% vs. 4%), and constipation (5% vs. 3%) [2].

Because memantine is not a stimulant, it does not raise heart rate, raise blood pressure, suppress appetite, or disrupt sleep architecture in the way amphetamine-based medications can. Patients with cardiac disease or hypertension who cannot tolerate stimulants sometimes find this profile reassuring.

Serious adverse events are rare. Post-marketing surveillance has identified isolated cases of Stevens-Johnson syndrome and other severe skin reactions; patients should discontinue and seek care for any new rash with systemic symptoms. Seizure threshold may be slightly lowered, though controlled trial data do not show a statistically significant increase in seizure rates.

Drug interactions are limited but real. Amantadine (another NMDA antagonist), ketamine, and dextromethorphan share the same binding site and should generally not be combined. Drugs that alkalinize urine, including some antacids taken at high frequency, may slow memantine clearance.

How Memantine Compares to Other Cognitive Medications

Patients and caregivers frequently ask how memantine relates to stimulant medications used for attention and cognition. The drugs address fundamentally different populations and mechanisms.

Modafinil (Provigil) and Armodafinil (Nuvigil)

Modafinil is a wakefulness-promoting agent FDA-approved for narcolepsy, shift-work sleep disorder, and obstructive sleep apnea with residual sleepiness. Its precise mechanism is still debated, but it appears to inhibit dopamine reuptake and activate orexin neurons. A 2002 meta-analysis of modafinil in healthy volunteers suggested modest improvements in attention and executive function during sleep deprivation, but effects during normal wakefulness are smaller and less consistent [6].

Armodafinil (Nuvigil) is the R-enantiomer of modafinil with a longer half-life (approximately 15 hours vs. 12 hours for modafinil) and a flatter plasma concentration curve that some patients find produces more sustained alertness without the afternoon peak-and-trough pattern.

Neither drug is approved for Alzheimer's disease or MCI. Both are Schedule IV controlled substances.

Methylphenidate (Ritalin, Concerta)

Methylphenidate blocks dopamine and norepinephrine reuptake transporters. The Multimodal Treatment Study of Children with ADHD (MTA Cooperative Group, N=579) demonstrated that medication management produced significantly greater symptom reduction than behavioral therapy alone over 14 months in children with ADHD [7]. In adults, a 2018 meta-analysis of 19 RCTs (Cortese et al., Lancet Psychiatry, N=2,066) ranked methylphenidate as the most effective ADHD medication in children and the comparator for adult trials [8].

For Alzheimer's patients with apathy, a small pilot trial (Mintzer et al., 2021, N=200) found methylphenidate improved apathy scores and caregiver-rated global function, though cognitive scores were not significantly changed [9].

Methylphenidate is a Schedule II controlled substance. It can raise blood pressure and heart rate, which matters in the older Alzheimer's population where cardiovascular comorbidity is common.

Amphetamine Salts (Adderall, Mydayis) and Dextroamphetamine

Mixed amphetamine salts release dopamine and norepinephrine from presynaptic terminals and block their reuptake, producing greater dopaminergic effect than methylphenidate at comparable clinical doses. The STEP-BD ancillary data and multiple ADHD trials confirm high effect sizes (Cohen's d approximately 0.9 to 1.1) for core ADHD symptoms.

Mydayis is a triple-bead extended-release amphetamine formulation approved for adults, designed for up to 16 hours of effect versus 8 to 12 hours for Adderall XR.

Amphetamines are Schedule II and carry a black-box warning for abuse potential and cardiovascular risk. They are not studied or approved for Alzheimer's disease.

HealthRX Clinical Framework: Matching the Medication to the Mechanism

| Patient Profile | First-Line Agent | Notes | |---|---|---| | Moderate-to-severe Alzheimer's | Memantine 20 mg/day IR (or 28 mg XR) | Add donepezil if not already prescribed | | Mild Alzheimer's | Donepezil, rivastigmine, or galantamine | Memantine not FDA-approved for mild disease | | ADHD (children) | Methylphenidate or amphetamine salts | MTA trial evidence; Schedule II | | ADHD (adults) | Amphetamine salts or methylphenidate | Cortese 2018 meta-analysis guidance | | Narcolepsy / shift-work sleepiness | Modafinil or armodafinil | Schedule IV; not for dementia | | Off-label MCI (no proven Rx) | No approved pharmacotherapy | Lifestyle, cardiovascular risk reduction |

Memantine in Combination with Cholinesterase Inhibitors

The combination of a cholinesterase inhibitor (donepezil, rivastigmine, or galantamine) plus memantine has a strong pharmacological rationale. Cholinesterase inhibitors increase acetylcholine by slowing its breakdown; memantine reduces glutamate-driven excitotoxicity. The two mechanisms do not overlap and do not share major toxicities.

The DOMINO-AD trial (NEJM, 2012) provided the best real-world evidence. Patients in the donepezil-plus-memantine arm had significantly better scores on the Standardized MMSE (SMMSE difference of 1.9 points, P<0.001) and Bristol ADL scale (difference of 3.0 points, P<0.001) compared to those who stopped both drugs [5].

The Namzaric fixed-dose capsule (memantine XR 28 mg / donepezil 10 mg) simplifies adherence for patients already stable on donepezil 10 mg. The FDA approved it in December 2014 [2]. Caregivers managing multiple pill burdens for patients with dementia often find the single-capsule formulation clinically meaningful.

Monitoring and Follow-Up

Clinicians prescribing memantine should check renal function (serum creatinine, BMP, or CMP) before initiation and at least annually, given that renal clearance governs drug levels. Cognitive assessments using the MMSE or Montreal Cognitive Assessment (MoCA) every six months give a structured picture of trajectory, though memantine's effect size means individual visit-to-visit fluctuations may exceed the drug's mean benefit.

Blood pressure monitoring is not specifically required by the memantine label (unlike stimulants), but Alzheimer's patients are frequently on antihypertensives and other cardiovascular medications. A complete medication reconciliation at every visit reduces interaction risk.

Discontinuation decisions should be individualized. When a patient reaches very severe dementia (MMSE below 3), the evidence base essentially ends, and the risk-benefit calculation shifts toward minimizing polypharmacy.

Practical Prescribing Considerations

Memantine is available as a generic, and the cost differential versus brand Namenda is substantial: generic memantine 10 mg tablets typically cost under $30 for a 60-tablet supply at major pharmacy chains, versus several hundred dollars for branded Namenda XR. Insurance formularies almost universally prefer generic IR or the generic XR (memantine ER).

The capsule form of memantine XR can be opened and sprinkled over applesauce for patients who cannot swallow capsules, per the FDA label [2]. This is especially useful for patients with dysphagia, a common problem in moderate-to-severe Alzheimer's disease.

Patients switching from memantine IR 10 mg twice daily to Namenda XR 28 mg once daily can make the transition the day after the last IR dose; no re-titration is required per prescribing information [2].

The American Geriatrics Society Beers Criteria 2023 does not list memantine as a potentially inappropriate medication for older adults, distinguishing it from many CNS-active drugs that carry explicit warnings in this population.

"Memantine remains one of two approved pharmacological approaches for Alzheimer's disease, and while its benefits are modest in absolute terms, it represents a meaningful option for patients whose disease has progressed beyond the mild stage," according to the 2023 practice guideline update from the American Academy of Neurology [10].